A Multicenter, Randomized, Double-blind, Parallel Group, Placebo controlled, Phase 3b Study to Evaluate the Safety and Efficacy of Benralizumab 30 mg sc in Patients with Severe Asthma Uncontrolled on Standard of Care Treatment (ANDHI)
Phase of Trial: Phase III
Latest Information Update: 11 Apr 2018
At a glance
- Drugs Benralizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms ANDHI
- Sponsors AstraZeneca
- 05 Apr 2018 Planned number of patients changed from 800 to 630.
- 25 Jul 2017 Status changed from not yet recruiting to recruiting.
- 05 Jun 2017 New trial record